Travere Therapeutics (NASDAQ: TVTX) reported Q4 EPS of $0.37, $0.41 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $129.69 million versus the consensus estimate of $145.23 million.

For earnings history and earnings-related data on Travere Therapeutics (TVTX) click here.